CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical corporation centered on identifying, building and commercializing therapies
CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical corporation centered on identifying, building and commercializing therapies